# NCT01886872 (NCT01886872)

> Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01886872
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia
- Interventions: Bendamustine Hydrochloride; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Ibrutinib; Laboratory Biomarker Analysis; Quality-of-Life Assessment; Rituximab
- Enrollment: 547
- Primary outcome: Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01886872